Access: This EU-OPENSCREEN-DRIVE chemoproteomics call 1 offers funding to enable transnational access to chemical proteomics and compound disposition facilities supporting a total of 3 projects.
Publication: Open access (gold or green) is required for any publication of access results. EU-OPENSCREEN-DRIVE funding must be clearly acknowledged by: “This project has received funding from the European Union´s Horizon 2020 research and innovation programme under grant agreement No 823893.”
Open access EU-OS chemical biology database (ECBD): Data will be deposited with a flexible privacy model for rapid and safe dissemination and exploitation. Users stay owner of their data. The optional hold period will be 36 months for data publication. There will be high standards of security and traceability of IP (citable indexing of data points (EUOS, DOI or URL) and links to originator labs for primary raw unprocessed data. Data are disseminated according to the FAIR data principles (i.e., Findable, Accessible, Interoperable and Re-usable), allowing communities across academia, SMEs and industry to benefit from EU-OPENSCREEN’s activities. Please read more about our EU-OPENSCREEN ERIC database on the link: https://www.eu-openscreen.eu/services/database.html.
Proposal and deadlines: Applicants will submit their proposals via EU-OPENSCREEN-DRIVE website, by connecting to the ARIA online submission platform. The online proposal submission will be open until September 30, 2019, 20:00 CET. Applicants will be notified about acceptance or rejection of their proposal within 12 weeks after the closure of chemoproteomics call 1.
ARIA: The ARIA application platform for EU-OPENSCREEN-DRIVE is handled by Instruct-ERIC. Although potential EU-OPENSCREEN-DRIVE users are requested to register with the ARIA system, the application, review, and reporting process will be handled by EU-OPENSCREEN-DRIVE.
Application step by step:
Click on “Begin a new proposal” and follow the instructions.
1. Proposal Details
Complete the fields with details of the desired research:
Research project title:*provide a title for your project.
Project overview, significance and objectives:*provide a detailed overview of the project and report on its significance and objectives including the rationale and the expected impact of the research.
Relevant publications:*please include up to 5 relevant publications.
Description of the scientific work:* please give a detailed description of up-to-date research and planned follow-up experiments. If possible, disclose structure of compound of interest for further feasibility assessment.
Is a cellular or organismal activity of at least 1 µM or lower confirmed?If yes, please give details.
Have the preliminary Structure Activity Relationships (SAR) been identified?*If yes, please give details including information on pan-assay interference (PAIN) analysis of the structure (add literature reference if available), availability of structurally similar active and non-active compounds, etc.
Is the SAR-informed synthesis of linker derivatives for functional immobilization in place?* please comment.
Indicate the amount of compound available for the project*
Indicate if a (bio)synthetic route is available (preferentially bearing functional groups for further modification, which would not interfere with activity): Please report source/reference of synthetic protocol and provide information about reaction scalability: <1 mg, 1-10 mg, >10 mg
Indicate the purity of compound (is it > 95%?)*
Indicate which methods have been used for purity determination.*
Comment on biological material/model to be used in the project and your capacity to provide it (e.g. indicate the amount of lysates or whole cells, cellular compartments, tissues of any given organism available for the project): please comment.
Describe assays (e.g. biochemical, phenotypic) which have been performed with the compound of interest: please comment.
Are in-vitro ADME data available? (e.g. permeability, plasma protein binding, metabolic stability):* please comment on availability of compound in-vitro data.
Are in-vivo pharmacokinetic data available (e.g. half-life, bioavailability, maximum tolerated dose (MTD), etc)? Please comment on availability of compound pharmacological data if applying for compound disposition studies.
If available, provide information on preliminary hypotheses around mode of action or target protein for compound to be tested: please comment.
Does the activity proposed within this call involve research using human cells or tissues(other than from Human Embryos/Foetuses)?*If yes, please specify.
Does the research activity proposed within this call involve research on animals?*If yes, please specify.
Please upload any additional document relevant for the evaluation of this proposal.
☐I agree to be the principal investigator of the submitted project as it is described in the present application.
☐I confirm that all relevant authorizations, declarations and accreditation from competent authority(ies) have been obtained in order to process the above mentioned samples and data through EU-OPENSCREEN-DRIVE, for the requested purposes, in full compliance with the applicable EU and National laws.*
☐All publications resulting or including data obtained through EU-OPENSCREEN-DRIVE will be published under Open Access.*
☐Legal requirements for exporting/importing materials to/from other countries have been met.*
☐I agree that EU-OPENSCREEN-DRIVE partners can exploit general information of my project for outreach and reporting purposes (respecting confidentiality of project specifics): In case that you do not agree, please give your explanation in the comment section.
Comments: please add any additional relevant comment and/or information.
2. Your Research Team
Choose which local researchers from your lab will be involved in the project.
Principal Investigator: The principal investigator is a scientist eligible by their institution to apply for grants. If you, the applicant, is not the selected PI the system will send an automatic message for authorization of the proposal. Please note that the user profile will be the reviewer's main source of information about the PI, applicant and team.
Note: If you select a Principal Investigator other than yourself they will be contacted by email to verify this submission.
Home Lab Colleagues: in addition to the applicant, please indicate other members of your home institution that will be part of the research project. Only scientists mentioned in this section will be eligible to access facilities (if applicable) if the proposal is approved. Please note that the user profile will be the reviewer's main source of information about the applicant and the team.
Note: Applicants (including PI and home lab colleagues which are mentioned in the proposal) should register for an ARIA account prior to the submission of the proposal or login directly if they are already registered with an ARIA account. Once registered, the applicants are required to follow ARIA instructions.
3. Exclude Reviewers
Feel free to exclude reviewers that may have a conflict of interest.
4. Confirm Proposal
Review the information you have entered and submit your proposal for moderation and review.
5. Accept terms and conditions of submission
Accept terms and conditions of the access routes you have selected.
6. Proposal submitted
Your proposal has been successfully submitted. You, the applicant, will receive a notification about acceptance or rejection of your proposal within 12 weeks after the closure of chemoproteomics call 1.